|
|
 |
|
Viewing report
|
|
|
|
European Blood Pathogen Inactivation Market
Frost & Sullivan, June 2010, Pages: 79
This study focuses on the blood pathogen inactivation market in Western Europe pertaining to the technologies that are currently in use and under development for pathogen inactivation of plasma, platelets and RBCs. Segment-wise revenue forecasting has been done for plasma and platelets. The market sizing and growth rates are pertaining to the seven key regions of Western Europe. The study also attempts to analyse the country-wise regulatory scenario for PR and PI technologies in Europe. General regulatory and market trends have also been discussed on a geographical basis. The study also analyses the challenges that influence this industry and the key market drivers and restraints.
This Frost & Sullivan research service titled European Blood Pathogen Inactivation Market provides revenue forecasts as well as an in-depth analysis of competitive structure and market trends. In this research, Frost & Sullivan's expert analysts thoroughly examine the following: platelets, red blood cells and plasma.
Market Overview
Need for Pre-emptive Pathogen Reduction and Pathogen Inactivation to Promote Market Prospects
Although remarkable advances have been made in the prevention of the major transfusion-transmitted diseases, long intervals have transpired between the first recognition of transfusion risk and the implementation of a preventive strategy. For hepatitis B virus, that interval was 30 years; for non-A non-B/hepatitis C virus, 15 years; and for human immunodeficiency virus, West Nile virus, Trypanosoma cruzi and bacteria, 3, 4, 5 and 18 years, respectively. In the existing reactive approach, there is a fundamental and inevitable delay before the government healthcare authorities can react; thus, infections are destined to occur. The continued emergence or re-emergence of transfusion-transmitted infections calls for a new paradigm of pre-emptive pathogen reduction (PR) and pathogen inactivation (PI). The European blood pathogen inactivation market is currently growing at a double-digit rate, which is significant even if it comes from a low base. This growth rate is likely to increase as more new products gain regulatory approval and enter the market.
Platelets are highly susceptible to bacterial contamination and therefore cannot be stored for more than 5 days. If the bacterial count is too low to detect, it has to be repeatedly cultured and sub-cultured to verify the number of colony-forming units, by which time, even platelet units that might have initially been usable, become contaminated and expire. “Therefore, in the case of platelets, PI makes good sense as it helps to extend the storage days from 5 to 7 days,” notes the analyst of this research. “Having two extra days also helps blood centres to manage their inventory better and could mean the difference between having and not having platelet units for transfusion in an emergency situation.”
Demonstrating Cost-benefit Analyses Key to Sustaining Market Momentum
Currently, there is no single PI method that is effective against all pathogens. This is a major drawback for the entire blood pathogen inactivation market, which leads to low uptake of PI techniques. In addition, it is impractical due to the labour intensiveness and cost issues, as currently, multiple inactivation techniques need to be applied to a unit of blood component. “This is anticipated to be a key challenge in this market until one of two things happens,” states the analyst. “One, the significant cost reduction of existing methods or two, the discovery of a single all-encompassing pathogen inactivation technique, neither of which seem to be on the visible horizon.”
There are indications from industry participants that they are focusing on the issue of performing economic cost-benefit analyses. This will raise confidence among healthcare authorities in the adoption of blood PI techniques. “Although the industry is currently focusing its resources towards clinical validation and gaining marketing approval in various regions in Europe, it is imperative that some resources be allocated towards performing cost-benefit analyses,” concludes the analyst.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Platelets
- Red blood cells
- Plasma
By Geography
- Germany
- France
- Italy
- Spain
- The United Kingdom
- Benelux (Belgium, the Netherlands and Luxembourg)
- Scandinavia (Sweden, Denmark, Norway and Finland)
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Systemic Fungal Infection Therapeutics Market - Australia
Systemic Fungal Infection Therapeutics Market- Taiwan
Therapeutic Apheresis - Global Strategic Business Report
Innovations in Combating Infectious Diseases: Opportunities in Therapeutics and Diagnostics through Application of Proteomics, Genomics, Nanotechnology, and Novel Sources of Lead Generation
Hepatitis C Therapeutics Market—Thailand
Antivirals - Global Strategic Business Report
Systemic Fungal Infection Therapeutics Market Research – Philippines
Pharmaceuticals Report Bundle
Systemic Fungal Infection Therapeutics Research – Malaysia
Systemic Fungal Infection Therapeutics Market – India
|
|
|
|
